ArashAshAlizadehMDPhD

Oncology • Stanford, CA

Moghadam Family Professor of Medicine (Oncology), Stanford University School of Medicine

Join to view full profile

Dr. Alizadeh is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Alizadeh's full profile

Already have an account?

Office
Stanford Comprehensive Cancer Center
875 Blake Wilbur Drive, MailCode MC-6560
Stanford, CA 94305
Phone+1 650-498-6000

Fax+1 650-724-1231

Summary

Ash Alizadeh, MD, is an oncologist based in Stanford, CA. He holds a fellowship in Hematology and completed his residency in Internal Medicine, both at Stanford Health Care-Sponsored Stanford University. Dr. Alizadeh is currently a Professor at Stanford University School of Medicine and has experience in various areas such as medical oncology, hodgkin lymphoma, non-hodgkin lymphoma, immunotherapy, and hematologic oncology. His research has been widely recognized, with publications in prestigious journals like NEJM, Cell, JCO, Blood, JAMA, JAMA Oncology, Nature, and Clinical Cancer Research. He is especially known for his contributions to the advancement of immune checkpoint inhibition therapy. He was awarded the CMS Meaningful Use Stage 1 Certification from EpicCare Ambulatory EMR, Epic Systems Corporation in 2011-2013.

Clinical Expertise

Lymphoma, Genes, Computational biology, Immunotherapy, Human Genome, Clinical Trials as Topic, Hematology, General medical oncology, Hematologic oncology, Leukemia, Multiple myeloma, Spinal lymphoma, Oropharyngeal lymphoma, Non-Hodgkin lymphoma, Angiocentric lymphoma, Medical oncology, Ophthalmic oncology

Education & Training

Stanford Health Care-Sponsored Stanford UniversityFellowship, Hematology, 2006 - 2010
Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 2004 - 2006
Stanford University School of MedicineClass of 2003

Work Experience

Stanford University School of MedicineAssociate Professor · April 2018 - Current
Stanford University School of MedicineAssistant Professor · January 2011 - Current
Stanford Health Care (Palo Alto, CA) ·

Certifications & Licensure

CA State Medical License 2005 - 2025
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Publications & Presentations

PubMed

3 citations
Analysis of Circulating Tumor DNA Predicts Outcomes of Short-Course Consolidation Immunotherapy in Unresectable Stage III NSCLC.
Soyeong Jun, Nikhil A Shukla, Greg Durm, Angela B Hui, Sha Cao
Journal of Thoracic Oncology. 2024-10-01
8 citations
CAR19 monitoring by peripheral blood immunophenotyping reveals histology-specific expansion and toxicity.
Mark P Hamilton, Erin Craig, Cesar Gentille Sanchez, Alain Mina, John Tamaresis
Blood Advances. 2024-06-25
ViPOR's Venom - Rationally Targeting DLBCL with Precision.
Jordan S Goldstein, Ash A Alizadeh
The New England Journal of Medicine. 2024-06-20

Abstracts/Posters

An Atlas of Clinically-Distinct Tumor Cellular Ecosystems in Diffuse Large B Cell Lymphoma
Ash A Alizadeh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Deep Sequencing of Viral Cell-Free DNA for Noninvasive Detection of Immunosuppression-Related Lymphoid Malignancies
Arash A. Alizadeh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Short Diagnosis-to-Treatment Interval Is Associated with Higher Levels of Circulating Tumor DNA in Aggressive B-Cell Non-Hodgkin Lymphoma
Ash A Alizadeh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Phased Variant Enrichment for Enhanced Minimal Residual Disease Detection from Cell-Free DNA
Ash A Alizadeh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Follicular Lymphoma Organoids for Investigating the Tumor Microenvironment
Ash A Alizadeh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Circulating DNA for Molecular Response Prediction, Characterization of Resistance Mechanisms and Quantification of CAR T-Cells during Axicabtagene Ciloleucel Therapy
Ash A Alizadeh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCL
Ash A Alizadeh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Maria-I: A Deep-Learning Approach for Accurate Prediction of MHC Class I Tumor Neoantigen Presentation
Arash A. Alizadeh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Towards Non-Invasive Classification of DLBCL Genetic Subtypes By Ctdna Profiling
Ash A Alizadeh, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Join now to see all